On Thursday, June 8, after market close, Enghouse will report its second quarter, 2017 results. Garcea thinks the company will post earnings of $0.47 and EBITDA of $24.4-million on revenue of $83.4-million. That’s better than the street consenseus take, which is for earnings of $0.45 and EBITDA of $23.1-million on a topline of $81.6-million.
Garcea notes that there has been something missing from the mix with Enghouse so far this year.
“ENGH has an established track record of value creation through acquisitions (34 in the last 18 years) –averaging three to six deals per year over the last few years. Although we haven’t seen any deals yet from ENGH this FY, economic factors are favourable for acquisitions, especially for small cap companies. ENGH targets companies in the $5-50M revenue range preferably with: (1) strong recurring revenue; (2) geographic, product or scale expansion; (3) mission critical solutions; and (4) high barriers to entry. The objective is for a cash payback within five to six years.”
In a research update to clients today, Garcea maintained his “Buy” rating and one-year price target of $65.00 on Enghouse Systems, implying a return of four per cent at the time of publication.
Garcea thinks Enghouse will post EBITDA of $102-million on revenue of $348-million in fiscal 2017. He expects those numbers will improve to EBITDA of $113-million on a topline of $379-million the following year.
Roth Capital Partners analyst Boobalan Pachaiyappan cut his target on ProMIS Neurosciences (ProMIS Neurosciences Stock Quote, Chart, News, Analysts, Financials… [Read More]
Roth Capital Partners analyst Philip Shen maintained his “Buy” rating and US$300.00 target on First Solar (First Solar, Stock Quote,… [Read More]
Roth Capital Partners analyst Bryan Baratian maintained his “Buy” rating and US$108.00 target on Hut 8 (Hut 8 Stock Quote,… [Read More]
Baskin Wealth Management president and chief investment officer Barry Schwartz named Topicus.com (Topicus.com Stock Quote, Chart, News, Analysts, Financials TSX:TOI)… [Read More]
On Oct. 29 Roth Capital Partners analyst Boobalan Pachaiyappan maintained his “Buy” rating and US$15.00 target on Atrium Therapeutics (Atrium… [Read More]
TD Cowen analyst David Kwan raised his target on Coveo Solutions (Coveo Solutions Stock Quote, Chart, News, Analysts, Financials TSX:CVO)… [Read More]